Skip to content
Fosfomycin tromethamine
Monurol (fosfomycin tromethamine) is a small molecule pharmaceutical. Fosfomycin tromethamine was first approved as Monurol on 1996-12-19. It is used to treat escherichia coli infections, gram-positive bacterial infections, klebsiella infections, proteus infections, and serratia infections amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
Trade Name
FDA
EMA
Monurol (generic drugs available since 2020-10-06)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fosfomycin tromethamine
Tradename
Company
Number
Date
Products
MONUROLZambonN-050717 RX1996-12-19
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
fosfomycin tromethamineANDA2023-02-06
monurolNew Drug Application2019-10-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
escherichia coli infectionsEFO_1001318D004927B96.20
gram-positive bacterial infectionsD016908
klebsiella infectionsEFO_1001353D007710
proteus infectionsEFO_1001130D011512
serratia infectionsEFO_1001421D016868
urinary tract infectionsEFO_0003103D014552N39.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
J01: Antibacterials for systemic use
J01X: Other antibacterials in atc
J01XX: Other antibacterials in atc
J01XX01: Fosfomycin
HCPCS
No data
Clinical
Clinical Trials
173 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
VomitingD014839HP_0002013R11.182023101070
NauseaD009325HP_0002018R11.021266531
Postoperative nausea and vomitingD020250EFO_000488822312725
NeoplasmsD009369C802222310
Breast neoplasmsD001943EFO_0003869C5023218
LymphomaD008223C85.91236
Ovarian neoplasmsD010051EFO_0003893C561135
PruritusD011537HP_0000989L292114
Healthy volunteers/patients314
LeukemiaD007938C95224
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Major depressive disorderD003865EFO_0003761F2299
Non-small-cell lung carcinomaD0022892114
Myeloproliferative disordersD009196D47.1123
Myeloid leukemia acuteD015470C92.0213
Colorectal neoplasmsD0151791113
Multiple myelomaD009101C90.01113
Gastrointestinal neoplasmsD005770C26.9112
Female genital neoplasmsD00583311
Germ cell and embryonal neoplasmsD00937311
Liver neoplasmsD008113EFO_1001513C22.011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AlcoholismD000437EFO_0003829F10.133
Marijuana abuseD002189EFO_0007191F12123
Myelodysplastic syndromesD009190D46123
HypertensionD006973EFO_0000537I10112
Type 2 diabetes mellitusD003924EFO_0001360E11112
Covid-19D000086382U07.111
AnalgesiaD00069811
Head and neck neoplasmsD00625811
GlioblastomaD005909EFO_0000515111
Lung neoplasmsD008175C34.9011
Show 10 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2033
Opioid-related disordersD009293EFO_0005611F1122
Tobacco use disorderD014029F1711
Non-hodgkin lymphomaD008228C85.911
Heroin dependenceD006556EFO_000424011
Substance-related disordersD019966EFO_0003890F1311
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.922
Plasma cell neoplasmsD05421922
Cognitive dysfunctionD060825G31.8411
Genetic polymorphismD01111011
Brenner tumorD00194811
Endometrioid carcinomaD01826911
Fallopian tube neoplasmsD00518511
CystadenocarcinomaD00353611
Narcotic-related disordersD00007952411
PancreatitisD010195EFO_0000278K8511
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFOSFOMYCIN TROMETHAMINE
INNfosfomycin
Description
Fosfomycin is a phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus. It has a role as an antimicrobial agent and an EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor. It is an epoxide and a member of phosphonic acids. It is functionally related to a phosphonic acid. It is a conjugate acid of a (1R,2S)-epoxypropylphosphonate(1-).
Classification
Small molecule
Drug classphosphoro-derivatives; antibiotics (Streptomyces strain)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@@H]1O[C@@H]1P(=O)(O)O.NC(CO)(CO)CO
Identifiers
PDB
CAS-ID23155-02-4
RxCUI4550
ChEMBL IDCHEMBL1200331
ChEBI ID
PubChem CID446987
DrugBankDB00828
UNII ID2N81MY12TE (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 10,826 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
4,899 adverse events reported
View more details